162269-78-5

Basic information

• Product Name: 1-Bromo-4-fluoro-2-(methoxymethoxy)benzene
• Synonyms: 1-Bromo-4-fluoro-2-(methoxymethoxy)benzene
• CAS NO: 162269-78-5
• Molecular Formula: C₈H₈BrFO₂
• Molecular Weight: 235.0503232
• Mol File: 162269-78-5.mol

Chemical Properties

• Boiling Point: 236.4±30.0 °C(Predicted)
• Appearance: /
• Density: 1.500±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-Bromo-4-fluoro-2-(methoxymethoxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Bromo-4-fluoro-2-(methoxymethoxy)benzene(162269-78-5)
• EPA Substance Registry System: 1-Bromo-4-fluoro-2-(methoxymethoxy)benzene(162269-78-5)

Safety Data

• Hazardous Substances Data: 162269-78-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Bromo-4-fluoro-2-(methoxymethoxy)benzene serves as a key intermediate in the organic synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 1-Bromo-4-fluoro-2-(methoxymethoxy)benzene is employed as a precursor in the synthesis of novel agrochemicals, contributing to the creation of more effective and environmentally friendly products for agricultural use.
Used in Materials Science:
1-Bromo-4-fluoro-2-(methoxymethoxy)benzene is utilized in the field of materials science for the development of advanced materials with specific properties, such as improved stability, reactivity, or selectivity in various applications.

Upstream product

• 107-30-2 chloromethyl methyl ether 
• 147460-41-1 2-bromo-5-fluorophenol 

Downstream Products

• 1037831-19-8 4-fluoro-1-iodo-2-methoxymethoxy-benzene 
• 1170264-39-7 1-but-1-ynyl-4-fluoro-2-methoxymethoxy-benzene 

Relevant articles and documents

A study of enantioselective syntheses by Sharpless asymmetric oxidation for aryl sulfoxides containing oxygen groups at the ortho position

Abstract: While ortho-alkoxy aryl sulfoxides including various substituents were synthesized by Sharpless asymmetric oxidation reaction, we optimized the reaction conditions and screened better combination of starting materials to obtain high enantioselectivity. The result suggested new information that electron-withdrawing substituents on the aromatic ring have a strong influence upon enantioselectivity of the products. Also, several chiral ligands for Sharpless asymmetric oxidation reaction were evaluated to improve the enantioselectivity. Graphic abstract: High enantioselectivity of ortho-alkoxy aryl chiral sulfoxides have been achieved by Sharpless oxidation reaction using Ti(O-i-Pr)4 and diethyl tartrate under anhydrous condition. In particular, the enantioselctivity of products was influenced by electron-withdrawing substituents on the aromatic ring, such as nitro, ester and aldehyde groups.[Figure not available: see fulltext.]

(E)-N-{3- [1-(8-FLUORO-11H-10-OXA-1-AZA-DIBENZO [A,D] CYCL0HEPTEN-5YLIDENE)-PROPYL]-PHENYL }-METHYNSULFON AMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID

The present invention provides Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and discloses met

An intra/intermolecular suzuki sequence to benzopyridyloxepines containing geometrically pure exocyclic tetrasubstituted alkenes

(Chemical Equation Presented) A route to enable the preparation of 5-benzylidenyl-benzopyridyloxepine analogues was developed to continue our research in the field of nuclear hormone receptor modulators. The key steps are1) a syn-stereoselective diboratio

Synthesis and biological activity of novel 2-(α- alkoxyimino)benzylpyridine derivatives as K+ channel openers

The search for novel K+ channel openers with a non-benzopyran skeleton, unlike cromakalim, led to the discovery of a new series of (Z)-2-(α- alkoxyimino)benzylpyridine derivatives. Synthesis was achieved by using a (Z)-dominant condensation reaction of henzoylpyridines with O- alkylhydroxylamines, followed by m-chloroperhenzoic acid (m-CPBA) oxidation. The compounds were tested for their vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2- and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for their effects on the coronary blood flow (CBF) after intracoronary injection in anesthetized dogs. A large number of the 2-(α- alkoxyimino)benzylpyridines strongly inhibited TEA and BaCl2-induced contraction, had no effect on 80 mM KCl-induced contraction, and increased the CBF to more than 200% of the basal flow at 10-30μg/dog. In particular, (Z)-2-[5-bromo-α-(tert-butoxyimino)-4-fluoro-2-hydroxybenzyl]-3- hydroxypyridine 1-oxide (7d) showed highly potent vasorelaxant activity (EC50=0.28μM) comparable to that of levcromakalim (EC50=0.17 μM), and gave a significantly longer-lasting increase (T ( 1/4 ) = 30 min) in the CBF compared to levcromakalim, nicorandil, nitroglycerin, or diltiazem (T( 1/4 )=5.2, 0.9, 0.4, and 2.2 min, respectively). It also exhibited a stable and long-lasting hypotensive effect (over 7h) upon oral administration of 1 mg/kg in spontaneously hypertensive rats (SHRs).